New findings from JAVELIN Bladder 100, IMvigor011, and CREST point to better biomarker-driven selection for bladder cancer maintenance immunotherapy.
Stay current on pivotal oncology trials with practice-changing results, recruiting studies, and key readouts relevant to community cancer care.
